Showing results (471-480 of 833) with videos related to

Sort By:
Pageof 84
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
Diabetes Technology & Therapeutics|April 25, 2022
Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe HypoglycemiaJulie Maria Bøggild Brøsen, Rikke Mette Agesen, Amra Ciric Alibegovic, et al.
Diabetes, Obesity & Metabolism|February 7, 2023
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemiaJulie Maria Bøggild Brøsen, Rikke Mette Agesen, Peter Lommer Kristensen, et al.
Nephron|October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving DialysisTobias Bomholt, Thomas Idorn, Filip K Knop, et al.
Frontiers in Endocrinology|December 17, 2021
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME TrialJacob K Jensen, Emilie H Zobel, Bernt J von Scholten, et al.
Cardiovascular Diabetology|December 20, 2025
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOWPeter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, et al.
Diabetes, Obesity & Metabolism|November 11, 2018
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markersHiddo J L Heerspink, C David Sjöström, Silvio E Inzucchi, et al.
Diabetes, Obesity & Metabolism|March 18, 2024
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trialStefan R Bornstein, Dick de Zeeuw, Hiddo J L Heerspink, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
Pageof 84